X0306 4 2020-10-20 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001750698 Vivo Capital IX, LLC C/O VIVO CAPITAL LLC 192 LYTTON AVENUE PALO ALTO CA 94301 0 0 1 0 0001750117 Vivo Capital Fund IX, L.P. C/O VIVO CAPITAL LLC 192 LYTTON AVENUE PALO ALTO CA 94301 0 0 1 0 Common Stock 2020-10-20 4 C 0 2780754 A 2780754 D Common Stock 2020-10-20 4 C 0 214281 A 2995035 D Common Stock 2020-10-20 4 P 0 250000 16.00 A 3245035 D Series B Preferred Stock 2020-10-20 4 C 0 2780754 D Common Stock 2780754 0 D Series C Preferred Stock 2020-10-20 4 C 0 214281 D Common Stock 214281 0 D Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein. /s/ Frank Kung, as a managing member of Vivo Capital IX, LLC 2020-10-20 /s/ Frank Kung, as a managing member of Vivo Capital IX, LLC, the general partner of Vivo Capital Fund IX, L.P. 2020-10-20